1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results-Reference-Cited by-同舟云学术

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

Published:2021-09 Issue: Volume:32 Page:S953-S954
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Paz-Ares L.,Goto Y.,Lim W.D.T.,Halmos B.,Cho B.C.,Dols M. Cobo,Gonzalez-Larriba J.L.,Zhou C.,Demedts I.,Atmaca A.,Baka S.,Mookerjee B.P.,Portella S.,Zhu Z.,Dharan B.,Reck M.

Funder

Boehringer Ingelheim

AstraZeneca

Novartis

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study;Journal of Clinical Oncology;2024-08-20

2. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan;JCO Global Oncology;2024-03

3. Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutations;ESMO Real World Data and Digital Oncology;2024-03

4. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial;Journal of Clinical Oncology;2024-01-10

5. Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials;Radiotherapy and Oncology;2024-01